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Background: The novel isoxazoline molecule fluralaner provides 12 weeks activity against fleas and 8 to 12 weeks
against tick infestations according to label claims.
Methods: This blinded, multi-center study in client-owned dogs evaluated the flea control provided by a single oral
fluralaner treatment (25–56 mg/kg; Bravecto™, Merck Animal Health) compared to a control group administered
three oral spinosad (30 – 60 mg/kg; Comfortis®, Elanco) treatments at 4-week intervals together with an amitraz
collar (9%, Preventic®, Virbac). Households were randomized (3:1 ratio) to either fluralaner (224 dogs, 118 households)
or control (70 dogs, 39 households). Within households, one primary dog with at least 10 live fleas at enrollment was
randomly selected for whole body flea counts every 4 weeks through Week 12; all dogs were followed for safety
until Week 12. Fluralaner dogs received two additional doses at Weeks 12 and 24 for further safety and palatability
observations through Week 26.
Results: Geometric mean flea count reductions from baseline for the fluralaner group at Weeks 4, 8, and 12 were
99.7%, 99.8%, and 99.8%, respectively; and 96.1%, 99.5%, and 99.6% for the spinosad controls. Percentages of flea-free
primary dogs at Weeks 4, 8, and 12 were 91.1%, 95.4%, and 95.3% for the fluralaner group; and 44.7%, 88.2%, and 84.4%
for the controls; the differences were significant at Weeks 4 (P < 0.0001) and 12 (P = 0.0370). Improvements in veterinarian
assessed flea allergy dermatitis (FAD) were observed in both groups. Fluralaner tablets were accepted free choice in over
90% of doses. The most common adverse event was vomiting, occurring in 7.1% of the fluralaner group and 14.3% of
the controls. No treatment related serious adverse events were reported.
Conclusions: A single treatment of dogs with the palatable fluralaner flavored chewable tablet provides a safe and
effective option for 12 weeks of flea control at least equivalent to that of 3 sequential treatments with spinosad tablets.
Linked to the high level of flea control was a substantial alleviation of associated signs of FAD.
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The last three decades have seen significant advances in
the treatment and control of canine ectoparasites. Topic-
ally applied pesticides, such as imidacloprid and fipronil,
were introduced in the 1990’s, and provided convenient
month long flea control and, for fipronil, additional activ-
ity against a range of tick species [1]. The use of such top-
ically applied products became a routine preventive health
practice in veterinary medicine. These products, and
others that were later introduced, either as single entities* Correspondence: cheyney.meadows@merck.com
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unless otherwise stated.or as combinations of molecules, reduced or eliminated
existing flea infestations and, for the month following
treatment, killed most reinfesting fleas before egg-laying
could begin. As a result, the need for adjunctive applica-
tion of environmental chemicals was largely eliminated
[2]. However, these topical ectoparasite control advances
presented limitations, including the need for careful and
sometimes challenging application by pet owners, poten-
tial reductions in effectiveness resulting from wash-off
during swimming or bathing, and owner concerns regard-
ing exposure in the household [3]. In 2007, an orally ad-
ministered pulicide (spinosad, Comfortis, Elanco) wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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fleas for one month following treatment [4]. While oral
spinosad resolved many concerns linked to topical prod-
ucts, it lacked efficacy against ticks and maintained the
need for owner compliance with monthly administration.
Fluralaner is a novel isoxazoline insecticide/acaricide
that offers the most recent advance in the control of ec-
toparasites of dogs, with 12 weeks of flea control and 8
to 12 weeks of tick control after a single oral dose. This
treatment was shown in a multi-centered field trial in
Europe to be superior to three sequential doses of fipro-
nil for flea control and also effective for tick control [5].
Bravecto (13.64% w/w flavored chewable tablet formula-
tion of fluralaner, Merck Animal Health) is an oral flurala-
ner formulation that is the first product approved by the
US Food and Drug Administration (NADA 141–426) to
provide 12 weeks activity against fleas and 8 to 12
weeks activity against the 4 common tick genera in the
United States (Amblyomma, Ixodes, Dermacentor and
Rhipicephalus) at a minimum dose of 25 mg/kg. Fol-
lowing oral administration to dogs with or without
food, fluralaner is rapidly absorbed, and provides 100%
effectiveness against fleas and ticks (Ixodes ricinus) within
1 day after treatment [6,7]. Blood levels are then sustained
and provide flea and tick effectiveness >95% for up to
12 weeks [6,7]. Safety has been demonstrated in puppies
administered repeated doses of up to 280 mg/kg (five times
the recommended rate) at 8-week intervals, beginning at
8 weeks of age, and in ivermectin-sensitive collies adminis-
tered doses of 3 times the approved dose rate [8,9].
The current field study was undertaken in the United
States to confirm the effectiveness over 12 weeks
(84 days) of a single owner-administered fluralaner fla-
vored chewable tablet dose to treat and control flea in-
festations. These results were compared to that of a
control group treated with spinosad and an amitraz col-
lar. Evidence of flea allergy dermatitis (FAD) was not an
enrollment criterion, but secondary objectives included
an assessment of improvement from baseline in signs of
FAD in a subset of dogs that presented with signs of
FAD. Furthermore, safety and palatability of fluralaner
tablets were assessed through 26 weeks (182 days) with
dogs receiving an additional two treatments at 12-week
intervals. Observational assessments of the tick control
provided by each study regimen were also completed.
Methods
This investigator-blinded, multicentric, positive-controlled
study was undertaken to assess the flea control effective-
ness of fluralaner tablets administered by owners to their
flea-infested dogs. Comparisons were made with a control
group receiving three sequential treatments of orally ad-
ministered spinosad at 4-week intervals plus an amitraz
collar. The study protocol complied with Good ClinicalPractice (VICH GL9), the International Guiding Principles
for Biomedical Research Involving Animals, and was
reviewed and approved by an ethics committee. Written
informed consent was obtained from each dog owner
prior to the commencement of any screening activities.
The study was conducted from August 2011 through June
2012 at 18 veterinary clinics located in nine different
states – Alabama, Florida, Kansas, Louisiana, Maine,
Missouri, North Carolina, Pennsylvania, and Texas. At
each site, the investigator was the clinic veterinarian who
was responsible for protocol supervision, oversight of
owner communication, animal examination including flea
allergy dermatitis (FAD) assessments, and supervision of
flea counts. To maintain appropriate blinding, the flea
treatment product assigned to each dog was dispensed by
non-blinded trained clinic personnel who were instructed
not to participate in collecting flea count data, physical ex-
aminations, or in the assessment of FAD. These personnel
were also responsible for any additional measures required
to ensure blinding, such as removing the amitraz collar
on enrolled control dogs before they were examined
by blinded personnel. Collars were replaced by owners
or non-blinded personnel once blinded activities were
completed.
Enrollment and participation
Eligible households were permitted to have up to 5
dogs, all of which had to be at least 12 weeks of age,
weigh at least 4.4 lb, and be in general good health.
However, dogs with chronic medical conditions (e.g.,
endocrinopathies, cardiovascular conditions, seizures)
were permitted to enroll if the condition was stabilized
prior to enrollment in the study. There were no breed
or gender restrictions, but households with pregnant
or lactating dogs were not eligible for enrollment.
Households in which dogs had exposure to non-confined
pets (other than dogs) that could harbor fleas (e.g.,
cats) were not eligible. Similarly, households were ex-
cluded if they contained another dog which did not
meet inclusion criteria.
Whole-body flea counts lasting at least 15 minutes per
dog were performed on all dogs by a trained individual
masked to treatment assignment. The criterion for
household enrollment was that at least one dog in each
household be infested with a minimum of 10 live fleas at
the screening assessment.
The following signs of FAD were separately graded by
a masked veterinarian (No Sign, Mild, Moderate, or Se-
vere): erythema [10,11], alopecia [11], papules [10,11],
scales [10], crusts [10] and excoriations [11]. When
present (i.e., Mild, Moderate, or Severe), each sign was
further assessed by the masked veterinarian concerning
anatomic location and whether or not the sign was indi-
cative of FAD. There was no protocol definition of FAD,
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ledge to determine if signs were indicative of FAD. Evi-
dence of FAD was not used as a criterion for enrollment
or randomization.
Enrollment restrictions based on prior use of flea con-
trol medications and treatments were based on product
label. Products labeled for monthly use had a minimum
30 day washout, products labeled for use every two
weeks had a 14 day washout, and products labeled for
weekly use had a seven day washout. Treatment that
could affect assessment of signs of FAD (for example
steroids, antihistamines, creams, ointments, baths, etc.)
was permissible, but any FAD data collected after a dog
was treated with such a product were excluded from
summary and analysis of FAD data.
No concomitant treatments for flea and/or tick infes-
tations were permitted during the study period. Groom-
ing, bathing, swimming, and other water activities were
permitted during the study, although participating dog
owners were asked to temporarily remove amitraz col-
lars prior to bathing. Grooming and bathing were not
allowed within 72 hours before protocol-scheduled flea
counting to avoid any impact on flea recovery.
To assess palatability of fluralaner tablets, owners were
instructed to first offer the dose by itself, for instance by
hand or in a bowl. The owner recorded if the dose was
freely taken within 1 minute or within 1 – 5 minutes. If
not, the owner could take alternative measures for vol-
untary uptake by the dog, such as hiding the tablet(s) in
food or treats. If these methods failed then the owner
could force feed the treatment or contact the investiga-
tor. The palatability of spinosad tablets was not assessed.
Owners were instructed to monitor dogs for one hour
after dosing and to be alert for any evidence of vomiting,
coughing, gagging, retching, drooling, salivating, or
other adverse signs. The owner was instructed to contact
the dispensing clinic to receive a replacement dose for
any dog which vomited or regurgitated the tablet within
1 hour after dosing.
Randomization and treatments
At each study site, qualifying households were assigned to
a treatment group according to a randomized complete
block design, with time of entry into the study as the
blocking factor. Within blocks, dogs were randomly
assigned in a 3:1 ratio to either the fluralaner group or the
control group consisting of spinosad + amitraz. Because
evidence of flea infestation was an enrollment criterion
and because there are numerous approved flea control
products, we decided against using a negative control
group. Commercially available spinosad was chosen as a
positive control product because at the time of study start
this was the only FDA-approved oral product that pro-
vided flea knockdown and a month of anti-flea activity.This product does not have labeled activity against ticks,
nor was there a FDA-registered product effective against a
range of tick genera. As tick control would be required in
some enrolling areas, we provided an amitraz collar due
to its known effectiveness against ticks and absence of
effect on fleas.
Each site had its own unique randomization table for
assignment of households to treatment group; all dogs
within a household received the same treatment. The
randomization tables also included a scheme for random
selection of a primary dog for households that had more
than 1 dog with ≥ 10 live fleas at enrollment. The pri-
mary dog was managed identically to the other dogs,
with the exception that the primary dog was the only
dog in the household for which flea counting was per-
formed for efficacy assessments at Visits 2, 3, and 4.
Fluralaner was administered at the label dose (25 –
56 mg/kg). Owners were instructed to administer treat-
ment at meal time, immediately before the dog was of-
fered its food. Additional doses of fluralaner tablets were
dispensed at Weeks 12 and 24 in accordance with each
dog’s body weight at those visits. Dogs in the control
group received a 9% amitraz tick collar plus spinosad
tablets at the labeled dose range of 30 to 60 mg/kg body
weight. Spinosad tablets were also dispensed at Weeks 4
and 8 in accordance with each dog’s body weight mea-
sured at Weeks 4 and 8. The first administration of the
allocated treatment(s) to any dog in the household,
which occurred on the day of or shortly after the first
visit, was classified as study Day 0.
Justification of sample size
Sample size calculation was based on significant reduc-
tion of flea count from baseline at each time point.
Using data from prior controlled studies demonstrating
the effectiveness of fluralaner against fleas, power calcu-
lations indicated that no more than 10 households
would be sufficient to provide 80% power to demon-
strate statistically significant (p < 0.05) reduction of flea
counts from baseline levels. To ensure broad regional
inclusion of households and dogs, the study targeted
enrollment of 100 households to be allocated to the flur-
alaner treatment group and 33 households to the con-
trol (spinosad + amitraz) group. The 3:1 enrollment
ratio provided sufficient households in the control
group for reference and comparison while maximizing
the opportunity for post-treatment safety observations
in the fluralaner group.
Efficacy assessments
All study dogs returned to the study site for assessment
visits every 4 weeks from Days 0 to 84, with a window ±
2 days at the Week 4 visit and ± 3 days at subsequent
visits. All sites were trained in study assessment procedures.
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maintained by having a non-blinded individual (either the
dog’s owner or a non-blinded member of clinic staff)
remove the tick collar from control dogs prior to perform-
ance of flea counts, FAD assessment, or physical examin-
ation. Non-blinded individuals were not permitted to
perform study tasks (flea count, FAD assessment, physical
examination) that required blinding. Whole body flea
counts were performed using a flea comb for at least 15 mi-
nutes. If fleas were recovered during the last minute of the
procedure, combing was continued for an additional 5 mi-
nutes until no fleas were recovered. All live fleas were
counted. Personnel at sites were also trained to manually
search for ticks using a whole body examination lasting for
5 minutes. During the study, any attached ticks collected
during clinic visits or by owners between visits were placed
into sealable alcohol-containing vials for later identification
by an experienced tick study investigator. Collected tick
data were observational, and none of the study products
were assessed for effectiveness against ticks. Fleas and ticks
were counted on primary dogs at all visits (Weeks 0, 4, 8,
and 12). For non-primary dogs, the protocol limited these
assessments to the enrollment visit.
The primary effectiveness criterion was based on live
flea counts in primary dogs as the experimental unit at
Weeks 4, 8, and 12 (Days 28, 56, and 84) compared to
baseline counts. For assessment of other variables
(safety/adverse events, FAD assessment, counting and
identification of ticks, palatability of fluralaner flavored
chewable tablets), each dog was the experimental unit.
The geometric mean live flea count of the primary
dogs was calculated separately for fluralaner and control
dogs for each time point (Days 28, 56, and 84). The
percent reduction at each time point was calculated
according to the equation:




where D0 = geometric mean at baseline, and Dx = geo-
metric mean on Day x (x = 28, 56, or 84).
The geometric mean flea count data were transformed
prior to analysis using the Y = loge(x + 1) transformation.
The log-transformed data were analyzed by a mixed lin-
ear model with repeated measures including treatment,
visit and treatment*visit as the fixed effects and site as
the random effect with the primary dogs in household as
the repeated subject.
The model least squares means were used for compar-
isons and were back-transformed to obtain the estimates
of geometric mean flea counts. A Kenward-Rogers ad-
justment was used to determine the denominator de-
grees of freedom for hypothesis testing.Comparisons were conducted within each treatment
group between the pre-treatment count and Days 28, 56
and 84 as well as between treatment groups at Days 28,
56, and 84. A two-sided test was used for each compari-
son at significance level α = 0.05. Statistical analysis was
performed with the software package SAS (SAS Institute
Inc., Cary, NC, USA, release 9.3).
Treatment was considered effective at each time point
if the mean live flea count reduction was 90% or greater
compared to Day 0, and the mean counts at Days 28, 56,
and 84 were statistically significantly different (P ≤ 0.05)
from and lower than Day 0. The percentages of flea-free
primary dogs (those with 0 fleas) at Days 28, 56, and
84 (Weeks 4, 8, and 12) were compared between flurala-
ner and spinosad + amitraz treatment groups using a
two-sided test with significant level α = 0.05. A non-
parametric asymptotic approach was used to obtain the
estimates for the differences of the percentages between
treatment groups. StatXact v9 was used to perform the
summary and analysis. All enrolled and treated dogs
were included in the analysis of clinical safety. Collected
tick data were observational, and none of the study
products were assessed for effectiveness against ticks.
Signs of FAD were evaluated for all study dogs at each
clinic visit. Assessment was performed by a masked vet-
erinarian, evaluating the severity (No Sign, Mild, Moder-
ate, and Severe) and anatomic location of the following
signs of FAD: erythema, alopecia, papules, scales, crusts,
and excoriation. If a sign was present, the veterinarian
also indicated if it was indicative of FAD. Finally, it was
recorded if the dog had received any medications (e.g.,
steroids, antihistamines, etc.) that could affect the as-
sessment of FAD. The presence of signs of FAD in dogs
that had not received any interfering medications was
summarized for both treatment groups. For each sign of
FAD, the percentage of dogs with the sign (Mild, Moder-
ate, or Severe) at enrollment that resolved (became No
Sign) at Week 12 without any interfering medications
was summarized.
Safety assessments
All study dogs were monitored until at least Week 12
(Day 84) for safety assessments, including clinic visits
every 4 weeks. Fluralaner-treated dogs were monitored
through Week 26, including clinic visits every 4 weeks
from Week 12 through Week 24 and a final study visit
on Week 26, 2 weeks after final fluralaner dose. Owners
were instructed to monitor closely each dog after treat-
ment administration, and to watch for possible adverse
events that might occur at any time during the course
of the study. Owners were asked to document all un-
favorable or unintended health events or any other ob-
servations, including the finding of attached ticks, in a
study diary.
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at baseline (Day 0) and Week 12 (Day 84). Blood and
urine were collected from all fluralaner-treated dogs at
baseline (Day 0), Week 12, and Week 26. Samples were
submitted for clinical pathology assessments (CBC,
chemistry screen, including liver and kidney panels, and
urinalysis) for determination of any potential adverse
treatment effects.
Results
Two hundred and ninety-four (294) dogs from 157 house-
holds were enrolled between August 2011 and December
2011 at 18 study sites, with 118 primary dogs assigned to
receive fluralaner (plus an additional 106 household dogs)
and 39 primary dogs assigned to receive spinosad +
amitraz (plus an additional 31 household dogs). Dogs
remained under study until June 2012. Approximately
50% (56/118 fluralaner and 19/39 control) of enrolled
households in each group contained a single dog. Age,
gender and weight of the two treatment groups were bal-
anced (Table 1). Approximately one third of dogs in each
group were described as mixed breed, with the most com-
mon breed identifications being Chihuahua (6.7% [15/224]
of fluralaner group dogs; 5.7% [4/70] of spinosad + amitraz
dogs), Jack Russell (4.0% [9/224] and 4.3% [3/70]), Labra-
dor retriever (4.0% [9/224] and 2.9% [2/70]) and Boxer
(3.1% [7/224] and 4.3% [3/70]).
In the population of household dogs, 8.0% (18/224) in
the fluralaner group (including eleven primary dogs) and
11.4% (8/70) in the spinosad + amitraz group (including
three primary dogs) were not included in the outcomes
assessments completed on Day 84. One non-primaryTable 1 Demographics of enrolled dogs and distribution
of numbers of dogs in each household
Fluralaner Spinosad + Amitraz
n = 224 n = 70
Age (years) Mean (SD) 5.1 (3.7) 5.3 (3.7)
Range 0.2 − 15.0 0.3 − 13.6
Weight (lb) Mean (SD) 37.3 (29.16) 38.7 (26.25)
Range 4.4 − 152.0 4.6 − 83.6
Gender Female, Intact 33 (14.7%) 14 (20.0%)
Female Spayed 82 (36.6%) 24 (34.3%)
Male, Intact 53 (23.7%) 9 (12.9%)
Male Neutered 56 (25.0%) 23 (32.9%)
Distribution of Household Sizes (number of dogs)
1 56/118 (47.5%) 19/39 (48.7%)
2 32/118 (27.1%) 12/39 (30.8%)
3 21/118 (17.8%) 6/39 (15.4%)
4 4/118 (3.4%) 1/39 (2.6%)
5 5/118 (4.2%) 1/39 (2.6%)dog in the fluralaner group was removed at the owner’s
request because it vomited following the first treatment;
the other two dogs in the household remained in the
study. All other removals were considered unrelated to
treatment and were due to diverse reasons including dis-
pensing error, unblinding, protocol violations including
failure to return for scheduled visits, and two deaths –
one dog was hit by a car and died, and another dog was
euthanized after a pre-existing cardiac failure condition
worsened.
Pre-treatment flea counts were similar between assigned
treatment groups (Table 2). In both treatment groups,
flea counts of the primary dogs were significantly reduced
(P < 0.0001 and the ≥ 90% efficacy was exceeded) com-
pared to baseline at each timepoint (Table 2). The per-
centage of primary dogs free of fleas in the fluralaner
group was significantly different from that in the spinosad +
amitraz group on Days 28 and 84 (P values <0.0001
and =0.0370, respectively); but was not significantly dif-
ferent on Day 56 (P value =0.1364).
No major treatment-related adverse events were re-
ported in either the fluralaner or the spinosad + amitraz
group. The most commonly reported adverse event in
each group was represented by emesis which was re-
ported in a greater percentage of dogs in the spinosad +
amitraz group than in the fluralaner group (Table 3).
There were no clinically relevant changes in complete
blood count, blood chemistry or urinalysis variables in
either treatment group.
At baseline (enrollment visit), in sites in Florida,
Missouri, Alabama, Pennsylvania and Louisiana, a total
of 47 attached ticks were found on 13 dogs assigned to
the fluralaner group and 11 attached ticks were found
on three dogs assigned to the spinosad + amitraz group.
At Visit 2, one fluralaner dog had one dead non-
engorged tick removed and at Visit 3 another fluralaner
dog had two ticks (one alive non-engorged and one dead
non-engorged tick) removed. At Visit 4, one control dog
had one alive non-engorged tick removed.
In addition to the 62 attached ticks collected by inves-
tigators, 14 ticks were collected by owners and returned
to the investigators. The 76 total ticks were submitted
for tick identification. Across these sites, the identified
tick genera were Ixodes (82.9% [63/76] of all submitted
ticks), Amblyomma (13.2% [10/76]), Dermacentor (2.6%
[2/76]) and Rhipicephalus (1.3% [1/76]).
Owner assessments of palatability of the fluralaner fla-
vored chewable tablets were available for 559 of 621
doses administered over the course of the study. The
palatability was consistent throughout the three doses
(Table 4). Approximately 80% (451/559) of fluralaner
doses were accepted free choice within 5 minutes after
being offered and an additional 12.5% (70/559) were
consumed with food or other treat. Therefore, a total of
Table 2 Primary dog geometric mean flea counts, percentage reduction from baseline, and flea-free dogs for treated
dogs at each visit
V1 V2 V3 V4
(enrollment) (Day 28) (Day 56) (Day 84)
Number of Primary Dogs
Fluralaner 117 113 108 106
Spinosad + Amitraz 39 38 34 32
Geometric mean flea count (95% CI)
Fluralaner 32.2 (27.1 – 38.2) 0.1 (0.0 – 0.2) 0.1 (0.0 – 0.1) 0.1 (0.0 – 0.1)
Spinosad + Amitraz 32.6 (23.6 – 44.9) 1.3 (0.7 – 2.0) 0.2 (0.0 – 0.4) 0.1 (0.0 – 0.2)
P-value for comparison* 0.9469 <0.0001 0.1766 0.2189
% effectiveness (reduction from baseline)
Fluralaner NA 99.7% 99.8% 99.8%
Spinosad + Amitraz NA 96.1% 99.5% 99.6%
% flea-free primary dogs
Fluralaner NA 91.1% 95.4% 95.3%
Spinosad + Amitraz NA 44.7% 88.2% 84.4%
P-value for comparison** NA <0.0001 0.1364 0.0370
“NA” indicates that the value or calculation is “not applicable”. No effectiveness comparison was performed at V1 and no primary dogs were flea-free at V1.
*- P-value for comparison of model least squares means parameter estimates.
**- P-value for comparison of percentages using non-parametric asymptotic approach.
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by dogs in this study.
Resolution of signs of FAD between enrollment and
Week 12 (Day 84) in dogs not receiving medications that
could affect the evaluation of FAD is summarized in
Table 5. Relative to baseline, at Week 12 (Day 84) there
was a high level of resolution of all signs of FAD in both
groups.
Discussion
A single fluralaner administration not only provided flea
count reductions at least equivalent to three monthly spi-
nosad treatments, but also resulted in significantly moreTable 3 Frequency of adverse events reported in dogs
randomized to receive either fluralaner flavored
chewable tablets or spinosad together with amitraz





(N = 224) (N = 70)
Emesis 16 (7.1%) 10 (14.3%)
Decreased appetite 15 (6.7%) 0 (0.0%)
Diarrhea 11 (4.9%) 2 (2.9%)
Lethargy 12 (5.4%) 5 (7.1%)
Polydipsia 4 (1.8%) 3 (4.3%)
Flatulence 3 (1.3%) 0 (0.0%)dogs being flea-free at Week 4 (fluralaner 91.1% [103/113]
vs spinosad 44.7% [17/38]) and at the final assessment at
Week 12 (fluralaner 95.3% [101/106] vs spinosad 84.4%
[27/32]) after the study began. This finding of high flurala-
ner efficacy parallels that reported from a European study
in which the flea control, including the percentage of flea-
free fluralaner-dogs at Week 4 post treatment, was super-
ior to that provided by topical fipronil/(s)-methoprene [5].
Such rapid achievement of flea-free status in treated dogs,
a status sustained for at least 12 weeks, points to flurala-
ner as providing a significant advance in the treatment
and control of canine flea infestations.
These reductions in flea counts and high rate of complete
flea elimination from study dogs translated into direct
clinical benefits in alleviating signs of FAD. In each of the
recorded signs of FAD, fluralaner treated dogs that en-
rolled with signs and had no interfering medications
showed improvements of 80% (scales [16/20]) to 95%
(crusts [21/22]). During protocol development, it was
decided that this registration study would limit FAD as-
sessments to those that could be objectively identified by
investigators. Subjective assessments of owner-reported
pruritus were therefore not completed. Nonetheless, be-
cause pruritus and other signs of FAD are caused by flea
bites, and because both treatments were effective in elim-
inating fleas, it can be expected that associated benefits
would include reductions in pruritus.
This was a real-world study designed to investigate the
potential of owner-administered fluralaner tablets as a
Table 4 Palatability of three sequential treatments with fluralaner flavored chewable tablets administered at 12 week
intervals
Step when dose accepted by dog Percentage of doses taken
1st Dose 2nd Dose 3rd Dose Total
~D0 ~D84 ~D168
(N = 207) (N = 188) (N = 164) (N = 559)
Free choice within 1 minute 158 (76.3%) 142 (75.5%) 116 (70.7%) 416 (74.4%)
Free choice within 1 – 5 minutes 11 (5.3%) 15 (8.0%) 9 (5.5%) 35 (6.3%)
Hidden in food or other treat 27 (13.0%) 17 (9.0%) 26 (15.9%) 70 (12.5%)
Dose force fed to dog 10 (4.8%) 10 (5.3%) 13 (7.9%) 33 (5.9%)
Investigator contacted for dosing 1 (0.5%) 4 (2.1%) 0 (0.0%) 5 (0.9%)
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The study was open-label for owners and for clinic staff
dispensing products, but all staff undertaking assess-
ments remained blinded throughout. The only treatment
instructions provided to owners were to administer the
tablets before a meal and according to package direc-
tions with the one between-treatment protocol differ-
ence related to recording palatability of the fluralaner
chewables. Two similar spinosad studies, only one of
which assessed palatability (in a manner similar to our
protocol) produced remarkably similar efficacy outcomes
[3,12]. The results from those studies are consistent with
the results we report, indicating that palatability assess-
ments did not affect results in any way.
At the enrollment visit, ticks were found on 24 study
dogs, indicating that there would be some challenge
with tick exposure during the study. Subsequent to
treatment, few ticks were found, consistent with the re-
ported effectiveness of the amitraz collar and supporting
the sustained anti-tick activity of fluralaner that has
been demonstrated in other field and laboratory studies
[5,7,13].
The absence of serious adverse events (Table 3) indi-
cates the safety of both products, with vomiting the
most commonly reported adverse event (reported inTable 5 Percentage of dogs with baseline flea allergy
dermatitis signs that resolved without interfering
medications at the final visit
Flea allergy
dermatitis sign
Fluralaner Spinosad + Amitraz
Erythema 89.3% (50/56 dogs) 70.6% (12/17 dogs)
Alopecia 88.2% (30/34) 80.0% (8/10)
Papules 92.3% (12/13) 100.0% (7/7)
Scales 80.0% (16/20) 88.9% (8/9)
Crusts 95.5% (21/22) 100.0% (7/7)
Excoriation 91.7% (11/12) 100.0% (6/6)7.1% [16/224] of dogs treated three times with fluralaner
tablets over the 26 week observation period (3 doses)
and in 14.3% [10/70] of the control group dogs over the
12 week observation period (3 doses of spinosad). In
other field studies of canine antiparasitic products,
vomiting rates have varied substantially – rates as high
as 18% and 15% have been reported to follow oral
treatment of dogs with ivermectin tablets and ivermec-
tin chewables, respectively, and a vomiting rate of
12% was reported to follow a single topical dose of
selamectin or oral dose of spinosad [12,14,15]. Other
adverse events were typically transient and mild, sup-
porting the safety profile of spinosad and amitraz and
indicating that fluralaner can be used safely in dogs. The
detailed owner observations, the inconsequential ad-
verse events associated with three sequential fluralaner
treatments over 26 weeks, and uneventful laboratory
analyses also confirmed earlier reports demonstrating
the safety of fluralaner in dogs [5,7-9].Conclusion
In conclusion, the results of this clinical study demon-
strate that a single treatment of dogs with the fluralaner
flavored chewable tablet, administered by owners, pro-
vides a level of flea control that is at least equivalent to
that provided by 3 sequential treatments with spinosad
tablets together with an amitraz collar. Linked to the
high level of flea control, a substantial alleviation of as-
sociated clinical signs of FAD was also seen. The flurala-
ner flavored chewable tablets were found to be highly
palatable for dogs. This study also demonstrated a favor-
able safety profile for fluralaner. The study therefore
demonstrates that fluralaner flavored chewable tablets
offer a significant advance in the treatment and control
of canine flea infestations, providing sustained 12-week
effectiveness with a single treatment.
Abbreviation
FAD: Flea allergy dermatitis.
Meadows et al. Parasites & Vectors 2014, 7:375 Page 8 of 8
http://www.parasitesandvectors.com/content/7/1/375Competing interests
Drs. Meadows, Guerino, and Sun are employed by Merck Animal Health.
Authors’ contributions
CM participated in the design of the study and was responsible for its
coordination and conduct and manuscript preparation. FG conceived of the
study and participated in its design. FS participated in the design of the
study and performed the statistical analyses. All authors read and approved
the final manuscript.
Acknowledgments
The authors thank the veterinarians and staff at the study sites for their
efforts in recruiting and working with the patients in this study. The authors
also thank Allyson L Smith and Carole Therrien and staff at The Veterinary
Consultancy LLC for their work with the study sites.
Received: 15 May 2014 Accepted: 4 August 2014
Published: 16 August 2014
References
1. Dryden MW, Payne PA, Smith V, Hostetler J: Evaluation of an imidacloprid
(8.8% w/w)–permethrin (44.0% w/w) topical spot-on and a fipronil
(9.8% w/w)–(S)-methoprene (8.8% w/w) topical spot-on to repel,
prevent attachment, and kill adult Ixodes scapularis and Amblyomma
americanum ticks on dogs. Vet Ther 2006, 7:173–186.
2. Rust MK: Advances in the control of Ctenocephalides felis (cat flea) on
cats and dogs. Trends Parasitol 2005, 21:232–236.
3. Dryden MW, Ryan WG, Bell M, Rumschlag AJ, Young LM, Snyder DE: Assessment
of owner-administered monthly treatments with oral spinosad or topical
spot-on fipronil/(S)-methoprene in controlling fleas and associated pruritus
in dogs. Vet Parasitol 2013, 191:340–346.
4. Snyder DE, Meyer J, Zimmermann AG, Qiao M, Gissendanner SJ, Cruthers LR,
Slone RL, Young DR: Preliminary studies on the effectiveness of the novel
pulicide, spinosad, for the treatment and control of fleas on dogs.
Vet Parasitol 2007, 150:345–351.
5. Rohdich R, Roepke RKA, Zschiesche E: A randomized, blinded, controlled
and multi-centered field study comparing the efficacy and safety of
Bravecto (fluralaner) against Frontline (fipronil) in flea- and tick-infested
dogs. Parasit Vectors 2014, 7:83.
6. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC: The effect of food on
the pharmacokinetics of oral fluralaner in dogs. Parasit Vectors 2014, 7:84.
7. NADA 141–126 Bravecto Fluralaner Chewable Tablets Dogs. [http://www.
fda.gov/downloads/animalveterinary/products/approvedanimaldrugproducts/
foiadrugsummaries/ucm399075.pdf]
8. Walther FM, Allan MJ, Roepke RKA, Nuernberger MC: Safety of fluralaner
chewable tablets (Bravecto), a novel systemic antiparasitic drug, in dogs
after oral administration. Parasit Vectors 2014, 7:87.
9. Walther FM, Paul AJ, Allan MJ, Roepke RKA, Nuernberger MC: Safety of
fluralaner, a novel systemic antiparasitic drug, in MDR1(−/−) Collies after
oral administration. Parasit Vectors 2014, 7:86.
10. Medleau L, Clekis T, McArthur TR, Alva R, Barrick RA, Jeannin P, Irwin J:
Evaluation of fipronil spot-on in the treatment of flea allergic dermatitis
in dogs. J Small Anim Pract 2003, 44:71–75.
11. Bonneau S, Skowronski V, Sanquer A, Maynard L, Eun HM: Therapeutic
efficacy of topical hydrocortisone aceponate in experimental flea-allergy
dermatitis in dogs. Aust Vet J 2009, 87:287–291.
12. Robertson-Plouch C, Baker KA, Hozak RR, Zimmermann AG, Parks SC, Herr C,
Hart LM, Jay J, Hutchens DE, Snyder DE: Clinical field study of the safety
and efficacy of spinosad chewable tablets for controlling fleas on dogs.
Vet Ther 2008, 9:26–36.
13. Estrada-Peña A, Ascher F: Comparison of an amitraz-impregnated collar
with topical administration of fipronil for prevention of experimental
and natural infestations by the brown dog tick (Rhipicephalus
sanguineus). J Am Vet Med Assoc 1999, 214:1799–1803.
14. Plue RE, Jernigan AD, Acre KE, Coleman MW, Currin ST, Ellis AJ, Lange RL,
Lange RL, Weiner DR: Field efficacy, safety and acceptability of ivermectinplus pyrantel in growing and adult dogs. In Proceedings of the Heartworm
Symposium ’92. Edited by Soll MD. Batavia, IL: American Heartworm Society;
1992:205–208.
15. Seward RL, Brokken ES, Plue RE: Ivermectin vs heartworm – a status
update. In Proceedings of the Heartworm Symposium ’86. Edited by Otto GF.
Washington, DC: American Heartworm Society; 1986:1–8.
doi:10.1186/1756-3305-7-375
Cite this article as: Meadows et al.: A randomized, blinded, controlled
USA field study to assess the use of fluralaner tablets in controlling
canine flea infestations. Parasites & Vectors 2014 7:375.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
